Method for inhibiting development of diabetic retinopathy

Abstract

The invention provides a method for inhibiting the progress of diabetic retinopathy, and the method specifically comprises the following steps: S1, inhibiting the formation of new vessels: reducing the formation of new vessels through tissue hypoxia caused by an inhibitor; s2, inhibiting the expression of TNF-a by using a high-dose anti-inflammatory drug: reducing the adhesion of retinal leukocytes; s3, improving microcirculation and reducing blood high viscosity, namely enhancing the flexibility of red blood cells through a medicine, reducing the high cohesiveness of the red blood cells, and inhibiting the synthesis and release of platelet aggregation factors; s4, delaying retinopathy by the calcium ion antagonist: inhibiting and removing oxygen free radicals, improving blood rheology and inhibiting platelet aggregation; and S5, improving microcirculation disturbance and retinopathy by using isoflavone substances: inhibiting the occurrence speed of the lesion and relieving symptoms. According to the method for inhibiting the progress of the diabetic retinopathy, the progress of the diabetic retinopathy can be inhibited through reasonable medicine intervention, so that the development of a therapeutic scheme of the diabetic retinopathy is promoted.

Description

Technical Field

[0001] The present invention belongs to the technical field of diabetic retinopathy, and in particular relates to a method for inhibiting the progression of diabetic retinopathy. Background Art

[0002] Diabetic retinopathy is one of the serious complications of diabetes and a common blinding eye disease. In developed countries, DR is one of the top three causes of blindness. With the improvement of people's living standards in my country, especially in economically developed large and medium-sized cities, the incidence of DR is increasing year by year, and the treatment of DR is also attracting more and more attention.

[0003] The occurrence and development of DR is a complex process related to multiple factors. Its basic pathological changes are the selective loss of pericytes at the earliest, followed by the formation of microaneurysms and thickening of the capillary basement membrane, further resulting in blood-retinal barrier destruction, capillary occlusion, arteriovenous changes, and even neovascularization and fibrosis, ultimately leading to retinal detachment and blindness.

[0004] At present, laser treatment for diabetic retinopathy is a treatment method that uses ophthalmic equipment and lasers to close the fundus, improve retinal ischemia and hypoxia, restore some retinal functions, prevent further vision loss, and avoid blindness. To some extent, it can save most of the patient's vision. Laser treatment has certain complications. For example, the laser needs to pass through the refractive medium, lens, and vitreous layer to reach the retina, which may cause cataracts and worsening vitreous opacities. Laser treatment has certain damage and side effects, and may cause macular edema, but in clinical practice, laser treatment is still an effective way to treat severe non-proliferative retinopathy and proliferative lesions.

[0005] Based on the risks of laser treatment, a method to inhibit the progression of diabetic retinopathy is proposed.

[0006] Therefore, in view of the shortcomings of the above scheme in actual production and implementation, it has been revised and improved. At the same time, in the spirit and concept of seeking improvement, with the assistance of professional knowledge and experience, and after many ingenuity and experiments, the present invention was created, and a method for inhibiting the progression of diabetic retinopathy is provided. Summary of the invention

[0007] The present invention provides a method for inhibiting the progression of diabetic retinopathy, which solves the problems in the prior art.

[0008] The technical solution of the present invention is achieved as follows: a method for inhibiting the progression of diabetic retinopathy, the method specifically comprising:

[0009] S1. Inhibition of new blood vessel formation: Tissue hypoxia caused by inhibitors leads to increased VEGF expression. VEGF is a protein that promotes the formation of new blood vessels. Inhibitor drugs can specifically bind to VEGF and inhibit its activity, thereby reducing the formation of new blood vessels.

[0010] S2. High-dose anti-inflammatory drugs inhibit TNF-a expression: reduce retinal leukocyte adhesion, reduce retinal ICAM-1 expression, and inhibit CD11a, CD11b, and CD18 expression;

[0011] S3. Improve microcirculation and reduce blood hyperviscosity: enhance the flexibility of red blood cells through drugs, reduce the high aggregation of red blood cells, inhibit the synthesis and release of platelet aggregation factors, and inhibit thrombosis caused by adenosine diphosphate;

[0012] S4. Calcium ion antagonists delay retinopathy: inhibit and scavenge oxygen free radicals, improve blood rheology, and inhibit platelet aggregation;

[0013] S5. Isoflavones improve microcirculation disorders and retinopathy: inhibit the rate of lesions and lead to symptom relief.

[0014] As a preferred embodiment of the method for inhibiting the progression of diabetic retinopathy, the inhibitor for inhibiting the formation of new blood vessels is a protein kinase inhibitor, and the protein kinase inhibitor is contacted with diacylglycerol to achieve protein phosphorylation and inhibit its activity.

[0015] Using the above scheme, retinal blood flow and protein amount are positively correlated with the degree of inhibition of protein kinase inhibitors. In addition to the direct activation effect of hyperglycemia on protein kinase inhibitors, growth factors, non-enzymatic glycation of proteins and other pathways are accompanied by the activation of protein kinase inhibitors. Therefore, inhibitors combined with better administration methods are conducive to the development of lesions.

[0016] As a preferred embodiment of the method for inhibiting the progression of diabetic retinopathy, the anti-inflammatory drug is specifically aspirin, which is used to reduce retinal ischemia and hemorrhage, with a dosage range of 75-150 mg / d.

[0017] With the above regimen, patients with retinopathy may be at risk of thrombosis, and aspirin can inhibit platelet aggregation and reduce the risk of thrombosis. Therefore, aspirin may help reduce retinal ischemia and hemorrhage.

[0018] As a preferred embodiment of the method for inhibiting the progression of diabetic retinopathy, the drug for improving microcirculation and reducing blood hyperviscosity is calcium hydroxyjasmonate, and the dosage range is 0.75-1.5 g / d.

[0019] Using the above regimen, calcium dobesilate can eliminate or alleviate the clinical signs of microangiopathy and reduce the inflammatory response to maintain the normal function of blood vessels.

[0020] As a preferred embodiment of the method for inhibiting the progression of diabetic retinopathy, the calcium ion antagonist is specifically an injection extracted from Chuanxiong, with a dosage range of 30-60 mg / d.

[0021] Using the above regimen, calcium ion antagonists can delay the characteristics of retinopathy, while also lowering blood pressure and reducing the effect of peripheral resistance.

[0022] As a preferred embodiment of the method for inhibiting the progression of diabetic retinopathy, the isoflavones are extracted from leguminous plants, and the dosage range is 30-40 mg / d.

[0023] By adopting the above scheme, isoflavones can inhibit retinal cell apoptosis and have a protective effect on diabetic retinal damage; at the same time, they can reduce the neovascularization and resistance index of diabetic patients.

[0024] After adopting the above technical scheme, the beneficial effects of the present invention are: reasonable drug intervention can inhibit the progression of diabetic retinopathy; protein kinase inhibits the formation of new blood vessels to reduce epiretinal membrane proliferation, thereby protecting retinal function, and cooperates with anti-inflammatory drugs to inhibit platelet aggregation and reduce the risk of thrombosis, while reducing oxygen consumption and making it easier for oxygen from the choroid to migrate to the inner layer of the retina to improve retinal blood circulation. DETAILED DESCRIPTION

[0025] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0026] Example 1

[0027] A method for inhibiting the progression of diabetic retinopathy, the method specifically comprising:

[0028] S1. Inhibition of new blood vessel formation: Tissue hypoxia caused by inhibitors leads to increased VEGF expression. VEGF is a protein that promotes the formation of new blood vessels. Inhibitor drugs can specifically bind to VEGF and inhibit its activity, thereby reducing the formation of new blood vessels.

[0029] S2. High-dose anti-inflammatory drugs inhibit TNF-a expression: reduce retinal leukocyte adhesion, reduce retinal ICAM-1 expression, and inhibit CD11a, CD11b, and CD18 expression;

[0030] S3. Calcium ion antagonists delay retinopathy: inhibit and scavenge oxygen free radicals, improve blood rheology, and inhibit platelet aggregation;

[0031] S4. Isoflavones improve microcirculatory disorders and retinopathy: inhibit the rate of lesions and lead to symptom relief.

[0032] Specifically, the inhibitor that inhibits the formation of new blood vessels is a protein kinase inhibitor. The retinal blood flow and protein amount are positively correlated with the degree of inhibition of the protein kinase inhibitor. In addition to the direct activation effect of hyperglycemia on the protein kinase inhibitor, the growth factors, non-enzymatic glycation of proteins and other pathways are accompanied by the activation of the protein kinase inhibitor. Therefore, the inhibitor combined with a better administration method is conducive to the development of the disease.

[0033] Specifically, the anti-inflammatory drug is aspirin, which can inhibit platelet aggregation and reduce the risk of thrombosis. Therefore, aspirin may help reduce retinal ischemia and hemorrhage. The dosage range is 75 mg / d.

[0034] Specifically, the calcium ion antagonist is an injection extracted from Chuanxiong. The calcium ion antagonist can delay the characteristics of retinopathy, while lowering blood pressure and reducing peripheral resistance. The dosage range is 30 mg / d.

[0035] Specifically, isoflavones are extracted from leguminous plants. They can inhibit retinal cell apoptosis and protect diabetic retinal damage. They can also reduce the neovascularization and resistance index of diabetic patients. The dosage range is 30 mg / d.

[0036] Example 2

[0037] A method for inhibiting the progression of diabetic retinopathy, the method specifically comprising:

[0038] S1. Inhibition of new blood vessel formation: Tissue hypoxia caused by inhibitors leads to increased VEGF expression. VEGF is a protein that promotes the formation of new blood vessels. Inhibitor drugs can specifically bind to VEGF and inhibit its activity, thereby reducing the formation of new blood vessels.

[0039] S2. High-dose anti-inflammatory drugs inhibit TNF-a expression: reduce retinal leukocyte adhesion, reduce retinal ICAM-1 expression, and inhibit CD11a, CD11b, and CD18 expression;

[0040] S3. Improve microcirculation and reduce blood viscosity: Enhance the flexibility of red blood cells through drugs, reduce the high aggregation of red blood cells, inhibit the synthesis and release of platelet aggregation factors, and inhibit thrombosis caused by adenosine diphosphate.

[0041] Specifically, the drug that improves microcirculation and reduces blood hyperviscosity is calcium hydroxybesilate. Calcium hydroxybesilate can eliminate or alleviate the clinical signs of microvascular disease and reduce inflammatory response to maintain normal blood vessel function. The dosage range is 0.75g / d.

[0042] A method for inhibiting the progression of diabetic retinopathy The progression of diabetic retinopathy can be inhibited by reasonable drug intervention to promote the development of treatment options for diabetic retinopathy.

[0043] The present invention provides a method for inhibiting the progression of diabetic retinopathy and opens up a new treatment plan for diabetic retinopathy. The above is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for inhibiting the progression of diabetic retinopathy, characterized in that: The method specifically includes: S1. Inhibition of new blood vessel formation: Tissue hypoxia caused by inhibitors leads to increased VEGF expression. VEGF is a protein that promotes the formation of new blood vessels. Inhibitor drugs can specifically bind to VEGF and inhibit its activity, thereby reducing the formation of new blood vessels. S2. High-dose anti-inflammatory drugs inhibit TNF-a expression: reduce retinal leukocyte adhesion, reduce retinal ICAM-1 expression, and inhibit CD11a, CD11b, and CD18 expression; S3. Improve microcirculation and reduce blood hyperviscosity: enhance the flexibility of red blood cells through drugs, reduce the high aggregation of red blood cells, inhibit the synthesis and release of platelet aggregation factors, and inhibit thrombosis caused by adenosine diphosphate; S4. Calcium ion antagonists delay retinopathy: inhibit and scavenge oxygen free radicals, improve blood rheology, and inhibit platelet aggregation; S5. Isoflavones improve microcirculation disorders and retinopathy: inhibit the rate of lesions and lead to symptom relief.

2. A method for inhibiting the progression of diabetic retinopathy according to claim 1, characterized in that: The inhibitor for inhibiting the formation of new blood vessels is a protein kinase inhibitor, which is in contact with diglycerol phthalate to achieve protein phosphorylation and inhibit its activity.

3. The method for inhibiting the progression of diabetic retinopathy according to claim 1, characterized in that: The anti-inflammatory drug is specifically aspirin, which is used to reduce retinal ischemia and hemorrhage, with a dosage range of 75-150 mg / d.

4. The method for inhibiting the progression of diabetic retinopathy according to claim 1, characterized in that: The drug for improving microcirculation and reducing blood hyperviscosity is calcium hydroxyjasmonate, and the dosage range is 0.75-1.5 g / d.

5. The method for inhibiting the progression of diabetic retinopathy according to claim 1, characterized in that: The calcium ion antagonist is specifically an injection extracted from Chuanxiong, with a dosage range of 30-60 mg / d.

6. The method for inhibiting the progression of diabetic retinopathy according to claim 1, characterized in that: The isoflavone substances are extracted from leguminous plants, and the dosage range is 30-40 mg / d.